Lupin: Co-Launches Dapagliflozin And Metformin Extended-Release Tablets In The United States

 22 Apr 2026 09:14 AM

Lupin: Co-Launches Dapagliflozin And Metformin Extended-Release Tablets In The United States

Lupin: USFDA Issues Form 483 With Three Observations For Its Somerset, New Jersey Manufacturing Site

 18 Apr 2026 02:07 PM

Lupin: USFDA Issues Form 483 With Three Observations For Its Somerset, New Jersey Manufacturing Site

Lupin: Company Forms A New Thailand Subsidiary For International Growth

 17 Apr 2026 05:23 PM

Lupin: Company Forms A New Thailand Subsidiary For International Growth

Lupin: Company Reaches Antitrust Settlement With Humana, Paying $30 Million; Lupin Denies All Claims

 17 Apr 2026 07:33 AM

Lupin: Company Reaches Antitrust Settlement With Humana, Paying $30 Million; Lupin Denies All Claims

Lupin: Co Gets US Approval For Dapagliflozin Plus Metformin Hydrochloride Tablets

 08 Apr 2026 05:28 PM

Lupin: Co Gets US Approval For Dapagliflozin Plus Metformin Hydrochloride Tablets

Lupin: Completes Visufarma B.V. Acquisition, Expanding Its Eye Care Portfolio To 60+ Branded Products And Strengthening Its Europe Presence.

 02 Apr 2026 10:59 AM

Lupin: Completes Visufarma B.V. Acquisition, Expanding Its Eye Care Portfolio To 60+ Branded Products And Strengthening Its Europe Presence.

Lupin: Unit Nanomi Plans To Buy Up To 43.38% Of Multicare Pharmaceuticals Philippines For as Much as USD 39.6 Million, With Goal Of Taking Full Ownership By May 2026

 01 Apr 2026 07:02 PM

Lupin: Unit Nanomi Plans To Buy Up To 43.38% Of Multicare Pharmaceuticals Philippines For as Much as USD 39.6 Million, With Goal Of Taking Full Ownership By May 2026

Lupin: Co. Receives Tentative Approval from U.S. FDA for Sugammadex Injection

 01 Apr 2026 08:33 AM

Lupin: Co. Receives Tentative Approval from U.S. FDA for Sugammadex Injection

Lupin: co Gets Tentative U.S. FDA Approval For Sugammadex Injection

 31 Mar 2026 01:16 PM

Lupin: co Gets Tentative U.S. FDA Approval For Sugammadex Injection

Lupin: Subsidiary Multicare Pharmaceuticals Philippines Buys Back 2,813,811 Shares, Boosting Nanomi’s Stake In MPPI From 51% To 56.28%.

 30 Mar 2026 09:42 AM

Lupin: Subsidiary Multicare Pharmaceuticals Philippines Buys Back 2,813,811 Shares, Boosting Nanomi’s Stake In MPPI From 51% To 56.28%.

Lupin: Gets Tentative U.S. FDA Approval For Pitolisant Tablets 4.45mg And 17.8mg

 25 Mar 2026 06:04 PM

Lupin: Gets Tentative U.S. FDA Approval For Pitolisant Tablets 4.45mg And 17.8mg

Lupin: U.S. FDA Gives Tentative Approval To Pitolisant Tablets

 25 Mar 2026 09:20 AM

Lupin: U.S. FDA Gives Tentative Approval To Pitolisant Tablets

Lupin: Company Announces Expansion of Manufacturing Facility in Dabhasa, India, Boosting Development and Manufacturing Strengths.

 19 Mar 2026 08:24 AM

Lupin: Company Announces Expansion of Manufacturing Facility in Dabhasa, India, Boosting Development and Manufacturing Strengths.

Lupin: Enters Licensing Deal With Zydus Lifesciences To Co-Brand Semaglutide Injection In India; Zydus Will Market As Semaglyntm, Mashematm, Altermetm, While Lupin Will Use The Names Semanext® And Livarise®.

 17 Mar 2026 12:02 PM

Lupin: Enters Licensing Deal With Zydus Lifesciences To Co-Brand Semaglutide Injection In India; Zydus Will Market As Semaglyntm, Mashematm, Altermetm, While Lupin Will Use The Names Semanext® And Livarise®.

Lupin: Company Reports Cargo Movement Affected Due To Container Delays At Ports From Europe And The Middle East.-Cnbc TV18

 09 Mar 2026 12:33 PM

Lupin: Company Reports Cargo Movement Affected Due To Container Delays At Ports From Europe And The Middle East.-Cnbc TV18

Lupin: Higher Oil Prices May Cause Increase in Solvent Costs

 09 Mar 2026 12:35 PM

Lupin: Higher Oil Prices May Cause Increase in Solvent Costs

Lupin: Morgan Stanley maintains Equal-Weight on Lupin Limited with Target Price Rs 2,386, noting the USFDA Form 483 with only two observations indicates manageable compliance risk, while FY26 is expected to deliver a second consecutive year of strong earnings growth.

 09 Mar 2026 09:12 AM

Lupin: Morgan Stanley maintains Equal-Weight on Lupin Limited with Target Price Rs 2,386, noting the USFDA Form 483 with only two observations indicates manageable compliance risk, while FY26 is expected to deliver a second consecutive year of strong earnings growth.

Lupin: USFDA Inspection At Lupin's Ankleshwar Plant Ends With Two Observations.

 09 Mar 2026 08:45 AM

Lupin: USFDA Inspection At Lupin's Ankleshwar Plant Ends With Two Observations.

Lupin: Goldman Sachs on Lupin Neutral, Target Price Rs 2275

 05 Mar 2026 09:05 AM

Lupin: Goldman Sachs on Lupin Neutral, Target Price Rs 2275

Lupin: Maharashtra GST Department Finishes Inspection With No Negative Findings; No Effect On Co's Financials

 02 Mar 2026 09:11 PM

Lupin: Maharashtra GST Department Finishes Inspection With No Negative Findings; No Effect On Co's Financials